Navigation Links
2009 is Healthy for Asia

Diverse impacts in the healthcare industry creates growth opportunities for healthcare and life science companies in the region

SINGAPORE, Jan. 13 /PRNewswire/ -- The credit crisis and the global economy meltdown has contributed to a significant shift in the Healthcare industry in 2009. Healthcare in Asia Pacific will not be affected as severely as the developed countries.


Dr. Louis Payet, Senior Consultant of the Healthcare Practice, Asia Pacific at Frost & Sullivan says that Asia will also benefit from this crisis as healthcare companies in the US and EU come under significant cost pressure.

"Healthcare Indices, while declining, have still outperformed the broader market. This implies that investors are still expecting positive activities within the industry in this region," says Dr. Payet.

He further adds that as countries like Japan and Singapore are already in recessions and most other regional economies are slowing, the healthcare market is still experiencing positive growth.

He also added that the governments are also responding to the crisis by trying to stimulate economic activity through alleviation of lack of liquidity and then injecting further stimulated growth via interest rate cuts and increased government spending.

Dr. Payet on a separate note cautions that the symptoms of the downturn should not be taken lightly. While the cost of debt may fall in 2009 it is anticipated that accessing debt will continue to be challenging.

"Pharmaceutical and medtech companies should be better positioned to deal with this situation than other healthcare groups. These companies typically have stronger cash flows and a lower reliance on debt funding. This creates opportunities for expansion and acquisition," comments Dr. Payet.

Are healthcare companies going to suffer their losses as the consumer discretionary spending decline?

According to Dr. Payet, the healthcare industry is perceived more as a defensive in comparison to other industries. More often products are viewed as essential goods that should be less affected by cyclical economic events.

Mr Simranjit Singh, Associate Director of the Healthcare Practice, Asia Pacific at Frost & Sullivan estimates the Asian Healthcare market in 2008 to be valued at about US $240 billion with the largest contributor being the Pharmaceuticals at 66.2 percent followed by the Medical Devices at 21.2 percent, Biotechnology at 6.7 percent, Clinical Diagnostics & Healthcare IT at 2.1 percent & Medical Imaging at 1.5 percent. In 2009, the Asian Healthcare Market is expected to grow by 5 to 10 percent.

"Due to the greater healthcare costs pressures, 2009 will also see the paradigm shift in healthcare spend in Asia from being treatment centric to move towards the 3 P's of healthcare - Predictive, Personalised & Preventative healthcare," comments Mr Singh.

Mr Singh further elaborates that the financial crisis presents an array of opportunities to key players in the healthcare industry especially Pharma & Medical technology companies. In a recent interview the CEO of Merck, Mr Richard Clark, highlighted that one of the key goals of Merck in 2009 was to look at distressed biotech companies that would be able boost Merck's revenue and beef up its pipeline.

Several Medtech companies like Philips Medical & GE Healthcare are looking for growth opportunities in emerging markets and they have taken bold steps with acquisitions or JVs with niche Medtech players in China & India such as Meditronics, Alpha X-ray & Shinva.

2009 represents an opportunity for Asia to takeover the mantle of leadership from the US & Europe to become the key driver of innovation and profitability for Healthcare companies.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Jasminder Kaur
    Corporate Communications - Healthcare, Asia Pacific
    DID: +65 6890 0937
    Mobile: +65 9062 7051

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
3. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
4. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
5. Isabellas Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic
6. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
7. A Scientist Dechipers the Code to Beautiful, Healthy Skin in The New Science of Perfect Skin
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
Breaking Biology News(10 mins):